Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin
| Autor: | J.W. de Fijter, O. M. H. Tysma, Bart O. Roep, P. Van De Linde, Frans H.J. Claas, D.L. Roelen, P. J. M. vd Boog, J. F. Elliott |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Graft Rejection Male Interleukin 2 Daclizumab Translational Studies medicine.medical_treatment T cell Immunology Antibodies Monoclonal Humanized Autoantigens Immune system Insulin-Secreting Cells Immune Tolerance Humans Immunology and Allergy Medicine IL-2 receptor Antilymphocyte Serum Immunosuppression Therapy business.industry Antibodies Monoclonal Receptors Interleukin-2 Immunosuppression Middle Aged Kidney Transplantation Recombinant Proteins eye diseases CD4 Lymphocyte Count Anti-thymocyte globulin Transplantation Cross-Sectional Studies Diabetes Mellitus Type 1 medicine.anatomical_structure Immunoglobulin G Interleukin-2 Female Pancreas Transplantation business Immunologic Memory Immunosuppressive Agents medicine.drug |
| Zdroj: | Clinical and Experimental Immunology. 149:56-62 |
| ISSN: | 1365-2249 0009-9104 |
| DOI: | 10.1111/j.1365-2249.2007.03400.x |
| Popis: | Summary Pancreas transplantation in type 1 diabetes patients could result in (re)activation of allo- and autoreactive T lymphocytes. Anti-thymocyte globulin (ATG) induction treatment is a successful, but broadly reactive anti-lymphocyte therapy used in pancreas and islet transplantation. A more selective alternative is daclizumab, a monoclonal antibody directed against the interleukin-2 receptor (CD25) on activated lymphocytes. We tested the hypothesis that daclizumab is more selective and has less immunological side effects than ATG. Thirty-nine simultaneous pancreas–kidney transplantation patients with type 1 diabetes were randomized for induction therapy with ATG or daclizumab. Auto- and recall immunity was measured cross-sectionally by lymphocyte stimulation tests with a series of auto- and recall antigens in 35 successfully transplanted patients. T cell autoimmunity to islets was low in both groups, except for a marginal but significantly higher reactivity against glutamic acid decarboxylase (GAD)65 in daclizumab-treated patients. The memory responses to recall antigens were significantly higher in the daclizumab-treated group compared to ATG-treated patients, specifically against purified protein derivative (PPD) (anti-bacterial immunity), Haemophilus influenzae virus matrix protein-1 (anti-viral immunity) and p53 [anti-tumour (auto)immunity]. These data imply that daclizumab is more specifically affecting diabetes-related immune responses than ATG. The autoimmunity is affected effectively after daclizumab induction, while memory responses towards bacterial, viral and tumour antigens are preserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|